{"id":478983,"date":"2021-04-20T09:28:04","date_gmt":"2021-04-20T13:28:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\/"},"modified":"2021-04-20T09:28:04","modified_gmt":"2021-04-20T13:28:04","slug":"cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\/","title":{"rendered":"Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol\u00ae Cyclo\u2122 in Alzheimer\u2019s Disease"},"content":{"rendered":"

<\/p>\n

Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol\u00ae<\/sup> Cyclo\u2122 in Alzheimer\u2019s Disease<\/b><\/p>\n

\nFDA feedback supports Company\u2019s Phase 2 development strategy for Alzheimer\u2019s disease asset; IND filing on track for H2 2021\n<\/p>\n

GAINESVILLE, Fla.–(BUSINESS WIRE<\/a>)–Cyclo Therapeutics, Inc.<\/a> (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that it has received feedback from the U.S. Food and Drug Administration (\u201cFDA\u201d) supporting the Company\u2019s development strategy to submit an initial new drug application (\u201cIND\u201d) application for a Phase 2 study of Trappsol\u00ae<\/sup> Cyclo\u2122 in the treatment of early Alzheimer\u2019s disease, following a positive Type B interaction.\n<\/p>\n

\n\u201cWe are encouraged by the feedback and recommendations from the FDA and are grateful for their support of our proposed Phase 2 development strategy for Trappsol\u00ae<\/sup> Cyclo\u2122 in the treatment of Alzheimer\u2019s disease. This interaction was an important step forward for our Alzheimer\u2019s disease program as we move forward with the filing of our initial IND. We are looking forward to supporting the advancement of this asset and the potential to bring an important treatment option to patients,\u201d commented Michael Lisjak, Chief Regulatory Officer, Senior Vice President for Business Development of Cyclo Therapeutics.\n<\/p>\n

\nThe Company is currently advancing its lead product candidate of Trappsol\u00ae<\/sup> Cyclo\u2122 in a pivotal Phase 3 study for the treatment of Niemann-Pick Type C (NPC1), expected to commence this quarter. Cyclo Therapeutics\u2019 Alzheimer\u2019s disease program is the second pipeline candidate program generated from the Company\u2019s platform technology. The Company is on track to file its IND for a Phase 2 study of Alzheimer\u2019s disease in the second half of this year.\n<\/p>\n

\nN. Scott Fine, CEO of the Company added, \u201cThe Cyclo Therapeutics team continues to make fundamental progress on all fronts, and I am very pleased with the outcome of our FDA interaction. We believe our Alzheimer\u2019s disease asset has potential as a disease modifying treatment and look forward to identifying the best strategic partner to advance this important program. Our focus and priority remain on advancing our pivotal Phase 3 study of Trappsol\u00ae<\/sup> Cyclo\u2122 towards approval to address the needs of the NPC community.\u201d\n<\/p>\n

\nAs previously announced, the Company filed an international patent application titled \u201cMethods for Treating Alzheimer\u2019s Disease,\u201d published as International Publication Number: WO 2020\/092107 Al<\/a>.\n<\/p>\n

About Alzheimer\u2019s Disease<\/b><\/p>\n

\nAlzheimer\u2019s disease is a progressive neurologic disorder that causes the brain to shrink (atrophy) and brain cells to die. Estimates vary, but experts suggest that more than 5.5 million Americans, most of them age 65 or older, may have dementia caused by Alzheimer\u2019s. Most people with Alzheimer\u2019s have the late-onset form of the disease, in which symptoms become apparent in their mid-60s. Early-onset Alzheimer\u2019s disease occurs between a person\u2019s 30s and mid-60s and represents less than 10 percent of all people with Alzheimer\u2019s. The early signs of the disease include forgetting recent events or conversations. As the disease progresses, a person with Alzheimer’s disease will develop severe memory and thinking skills impairment, then lose ability to learn, reason, make judgments, communicate and carry out daily activities. Medications may temporarily improve or slow progression of symptoms, however there is currently no treatment that cures Alzheimer’s disease or alters the disease process in the brain.\n<\/p>\n

About Cyclo Therapeutics<\/b><\/p>\n

\nCyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company\u2019s Trappsol\u00ae<\/sup> Cyclo\u2122, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547<\/a>, NCT02912793<\/a> and NCT03893071<\/a>). The company is planning an early phase clinical trial using Trappsol\u00ae<\/sup> Cyclo\u2122 intravenously in Alzheimer\u2019s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer\u2019s Disease (NCT03624842<\/a>). Additional indications for the active ingredient in Trappsol\u00ae<\/sup> Cyclo\u2122 are in development. For additional information, visit the company\u2019s website: www.cyclotherapeutics.com<\/a>.\n<\/p>\n

Safe Harbor Statement<\/b><\/p>\n

\nThis press release contains \u201cforward-looking statements\u201d about the company\u2019s current expectations about future results, performance, prospects and opportunities, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering. Statements that are not historical facts, such as \u201canticipates,\u201d \u201cbelieves\u201d and \u201cexpects\u201d or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company\u2019s future performance include the company\u2019s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company\u2019s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company\u2019s filings with the Securities and Exchange Commission, including, but not limited to, the company\u2019s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210420005277\/en\/<\/a><\/span><\/p>\n

Investor Contact:
\n<\/b>
JTC Team, LLC
\n
Jenene Thomas
\n
(833) 475-8247
\n
CYTH@jtcir.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Florida<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Clinical Trials Research Pharmaceutical Science Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol\u00ae Cyclo\u2122 in Alzheimer\u2019s Disease FDA feedback supports Company\u2019s Phase 2 development strategy for Alzheimer\u2019s disease asset; IND filing on track for H2 2021 GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that it has received feedback from the U.S. Food and Drug Administration (\u201cFDA\u201d) supporting the Company\u2019s development strategy to submit an initial new drug application (\u201cIND\u201d) application for a Phase 2 study of Trappsol\u00ae Cyclo\u2122 in the treatment of early Alzheimer\u2019s disease, following a positive Type B interaction. … <\/p>\n

Continue reading “Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol\u00ae Cyclo\u2122 in Alzheimer\u2019s Disease”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-478983","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol\u00ae Cyclo\u2122 in Alzheimer\u2019s Disease - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol\u00ae Cyclo\u2122 in Alzheimer\u2019s Disease - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol\u00ae Cyclo\u2122 in Alzheimer\u2019s Disease FDA feedback supports Company\u2019s Phase 2 development strategy for Alzheimer\u2019s disease asset; IND filing on track for H2 2021 GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that it has received feedback from the U.S. Food and Drug Administration (\u201cFDA\u201d) supporting the Company\u2019s development strategy to submit an initial new drug application (\u201cIND\u201d) application for a Phase 2 study of Trappsol\u00ae Cyclo\u2122 in the treatment of early Alzheimer\u2019s disease, following a positive Type B interaction. … Continue reading "Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol\u00ae Cyclo\u2122 in Alzheimer\u2019s Disease"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-20T13:28:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210420005277r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol\u00ae Cyclo\u2122 in Alzheimer\u2019s Disease\",\"datePublished\":\"2021-04-20T13:28:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\\\/\"},\"wordCount\":973,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210420005277r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\\\/\",\"name\":\"Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol\u00ae Cyclo\u2122 in Alzheimer\u2019s Disease - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210420005277r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-04-20T13:28:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210420005277r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210420005277r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol\u00ae Cyclo\u2122 in Alzheimer\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol\u00ae Cyclo\u2122 in Alzheimer\u2019s Disease - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol\u00ae Cyclo\u2122 in Alzheimer\u2019s Disease - Market Newsdesk","og_description":"Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol\u00ae Cyclo\u2122 in Alzheimer\u2019s Disease FDA feedback supports Company\u2019s Phase 2 development strategy for Alzheimer\u2019s disease asset; IND filing on track for H2 2021 GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that it has received feedback from the U.S. Food and Drug Administration (\u201cFDA\u201d) supporting the Company\u2019s development strategy to submit an initial new drug application (\u201cIND\u201d) application for a Phase 2 study of Trappsol\u00ae Cyclo\u2122 in the treatment of early Alzheimer\u2019s disease, following a positive Type B interaction. … Continue reading \"Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol\u00ae Cyclo\u2122 in Alzheimer\u2019s Disease\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-20T13:28:04+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210420005277r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol\u00ae Cyclo\u2122 in Alzheimer\u2019s Disease","datePublished":"2021-04-20T13:28:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\/"},"wordCount":973,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210420005277r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\/","name":"Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol\u00ae Cyclo\u2122 in Alzheimer\u2019s Disease - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210420005277r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-04-20T13:28:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210420005277r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210420005277r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-proceed-with-ind-filing-for-phase-2-trial-using-intravenous-trappsol-cyclo-in-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol\u00ae Cyclo\u2122 in Alzheimer\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/478983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=478983"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/478983\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=478983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=478983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=478983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}